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Abstract 
Acute myeloid leukemia (AML) is a cancer that develops when hematopoietic stem cells 
in the bone marrow transform into malignant cells and subsequently grow and replicate 
aberrantly. Autophagy, a pathway by which cellular components are sequestered and degraded in 
response to a variety of signals, is modified in AML. Here, we sought to understand the 
mitochondria-specific changes that occur in autophagy-deficient leukemia cells by silencing the 
genes ATG7, BNIP3L, or SQSTM1. We examined mitochondrial function using the probe 
rhodamine 123 (Rho 123), which accumulates according to the mitochondrial membrane 
potential (ΔΨM). We examined mitochondrial health using two probes: dihydroethidium (DHE): 
a probe for the main mitochondrial reactive oxygen species (ROS) superoxide, and  2’, 7-
dichlorodihydrofluorescein diacetate (H2DCFDA): a broad-range probe for other ROS. In all 
knockdowns, Rho 123 was increased indicating hyperpolarization of ΔΨM, and DHE was 
increased indicating accumulation of superoxide, however the fluorescent product of H2DCFDA 
was decreased indicating lower levels of other ROS. Taken together, these results indicated 
mitochondrial dysfunction in the gene-silenced lines. We measured mitochondrial content using 
the fluorescent probe nonyl acridine orange and quantitative polymerase chain reaction analysis 
of mitochondrial DNA (mtDNA) – both of which indicated no significant changes in 
mitochondrial content.  We performed a serum starvation and dose-response analysis using an 
autophagy activator to demonstrate the effects of these knockdowns on autophagy dynamics - 
which indicated altered autophagy. Finally, we ran a dose response which demonstrated that 
AML cells with deficiencies in autophagy proteins are more sensitive to mitochondrial-targeting 
drugs but not DNA-targeting drugs, suggesting that the former classes may provide an excellent 
opportunistic therapy for AML patients with substantial autophagy deficits.  
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Chapter 1: Introduction 
 
1.1 Cancer Genetics  
Cancer is a term for a group of heterogeneous diseases characterized by aberrant cell 
growth and uncontrolled proliferation. Various cell types can transform into cancer cells when 
mutations arise in key regions of the genetic material, deoxyribonucleic acid (DNA). Cancer-
causing mutations may arise as chance mistakes in DNA replication, as a result of an infection or 
disease, or due to DNA damage caused by physical or chemical agents (i.e., mutagens)2. These 
mutations can be the result of insertions, deletions, or translocations of genetic material, leading 
to changes in function or expression of transcribed proteins. Many of the known cancer-related 
genes affect cell survival, DNA damage repair, angiogenesis, metastasis, or regulation of cell 
cycle progression– providing a means to achieve aberrant proliferation2.  
 
1.1.1 Acute Myeloid Leukemia  
Leukemia is a cancer which arises when blood cells in the bone marrow are transformed 
by mutations, and produce undifferentiated, aberrantly growing blast cells3.  Clinically and 
pathologically, leukemia can be classified as being acute or chronic - based on the speed of 
progression, and myelogenous or lymphocytic - based on the lineage from which the leukemic 
cells diverge4. Acute myeloid leukemia (AML) is thus a rapidly progressing leukemia that 
diverges from the myeloid lineage. Formation of blasts in AML occurs at the expense of 
producing healthy myeloid-derived blood cells, resulting in a deficit of functional red blood 
cells, white blood cells, dendritic cells, and platelets, which can lead to death. Figure 1.1 
provides an overview of hematopoiesis and leukemic cell development.  
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Variable genetic alterations can result in the transformation to AML, creating 
heterogeneous leukemic cell populations between patients and within an individual4,5. With 
evidence that patient outcomes are inextricably linked to leukemia genetics, the search for genes 
which can serve as prognostic markers for AML has become increasingly important6. Currently 
prognostics are stratified based on a particular set of genes which include tyrosine kinases and 
transcription factors involved in proliferation, differentiation, and survival6. Cytogenics and 
molecular genetic tests provide a means to assess these molecular alterations6.  
 
 
MacrophagePlatelets Neutrophil EosinophilErythrocyte
Myeloid
stem6cell
Lymphoid
stem6cell
Hematopoietic
stem6cell
Pluripotent
stem6cell
NK6cell T Cell B6Cell
Basophil
Leukemic
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LeukemicBlasts6
Dendritic Cell
Dendritic Cell
Figure 1.1 Hematopoiesis and AML Development 
(A) Normal hematopoiesis: a common progenitor cell diverges to produce the myeloid and 
lymphoid lineages. (B) A leukemic stem cell derived from the myeloid lineage produces 
immature, intermediately differentiated blasts at the expense of producing healthy blood cells 
of the myeloid lineage. Images adapted from Servier Medical Art by Servier, licensed under 
CC BY 3.0.   
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1.1.2 Epidemiology 
The genetic defects from which AML arises can be hereditary, resultant from a blood 
disorder, or caused by exposure to a mutagenic agent (e.g. radiation, benzene, formaldehyde, or 
past chemotherapy)7,8,9. Adult AML is considered separately from childhood AML, for which the 
latter’s prognoses are typically more favourable10. In 2010, there were 1215 new cases and 971 
deaths from adult AML in Canada, with the median age of diagnosis being 6611,12. With a five 
year survival rate of less than 30% in Canada, there is a pressing need to uncover targeted 
therapies with better efficacy and fewer side effects than the current gold standard treatment10,13.  
 
1.1.3 Treatment of AML  
Since the early 1970’s the gold standard chemotherapy for AML has consisted of 
cytarabine combined with an anthracycline14. Cytarabine, an antimetabolite drug, exerts its 
effects by combining a cytosine base with arabinose instead of deoxyribose, thus disrupting 
DNA replication15. Anthracyclines such as daunorubicin, doxorubicin, and idarubicin, intercalate 
with DNA and inhibit the action of topoisomerase II, the enzyme responsible for creating 
transient breaks in the phosphodiester backbone to facilitate the un-winding of tangled DNA 
during replication13,16,17.  
As cancer is often attributed to uncontrollable cell replication, inhibiting essential 
processes in the replication cycle is a commonly harnessed therapeutic option18. In many 
cancers, increased proliferation contributes to replication-associated DNA damage which renders 
cancer cells more sensitive to drugs targeting DNA repair pathways18. Unfortunately, the 
effectiveness of these therapy options is limited by the susceptibility of healthy replicating cells 
to succumb to the same fate19. Furthermore, DNA damage in healthy cells can result in the 
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development of secondary malignancies and dose-limiting toxicities 20. Small advances in the 
study of cancer cell dysfunction continues to yield promise for the discovery of more selective 
therapies.  
 
1.2 Autophagy  
Cellular homeostasis is dependent on a balance of synthesis and destruction of cellular 
components. Though other mechanisms provide a means to achieve protein catabolism (e.g., the 
ubiquitin proteasome system), autophagy is unique in its ability to attend to the bulk of cellular 
components21. At basal level, autophagy acts as a mechanism of quality control; however, it can 
be initiated in response to cellular stress as an adaptive survival mechanism to increase the 
turnover of cellular components to release their basic units for the cell’s immediate needs22. 
Research in this field continues to uncover new proteins and functions, allowing for a better 
understanding of cellular homeostasis.      
 
1.2.1 Discovery [Types, Terminology]   
Analyses of the starvation response in yeast in the early 1990s paved the way for our 
current understanding of the molecular basis of autophagy, and allowed for the identification of 
40 autophagy-related (ATG) proteins, most of which have now been described in mammals23,24. 
These proteins, along with a variety of other signaling and modulating molecules, mediate the 
complex sequence of membrane remodeling and trafficking pathways that are necessary for 
targeted destruction of intracellular components.  
The most common classification system of autophagy is based on differences in the 
substrate to be degraded and the mode of delivery to the lysosome, which contains digestive 
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hydrolases. Macroautophagy (the focus of this research, and hereby referred to as just 
“autophagy”) refers to autophagy involving a double-membraned vacuole known as the 
autophagosome, which sequesters cytoplasmic components in either a bulk or cargo-specific 
manner before fusing with a lysosomal vacuole25. In contrast, microautophagy implies the direct 
uptake of cytoplasmic components by the lysosomal vacuole, which again can function in a bulk 
or cargo-specific manner25,26,27. Finally, chaperone-mediated autophagy (CMA) denotes a form 
of autophagy in which proteins are recognized at specific motifs and delivered to a lysosome by 
a chaperone protein28. Figure 1.2 depicts the three kinds of autophagy. 
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Lysosomal
Hydrolases
A).Macroautophagy
Phagophore Autophagosome Autophagolysosome
Lysosomal
Hydrolases
Cargo
B).Microautophagy
Lysosome
C).Chaperone;Mediated.Autophagy
Chaperone.Protein
Cargo
Lysosome
Receptor
Figure 1.2 Types of Autophagy  
A) Macroautophagy refers to autophagy involving a double-membraned vesicle called an 
autophagosome, which sequesters cellular components before fusing with a lysosome 
containing hydrolases25. B) Microautophagy is the direct uptake of cellular components, which 
are digested by lysosomal hydrolases25. C) Chaperone-mediated autophagy involves a 
chaperone (ex. HSC70 and co-chaperones) which binds KFERQ-motif containing substrates 
and brings them to a lysosomal receptor (ex. LAMP2A) where it will be degraded200. Images 
adapted from Servier Medical Art by Servier, licensed under CC BY.    
 7 
While autophagy was initially regarded as a simple bulk process in which a portion of 
cytoplasm was engulfed in response to cell stress, we now know that cargo-selective autophagy 
mechanisms also exist and are both common and necessary for a variety of homeostatic and cell-
specific tasks29. Autophagy can target mitochondria (mitophagy), peroxisomes (pexophagy), 
ribosomes (ribophagy), lipid stores (lipophagy), the endoplasmic reticulum (ERphagy), etc. with 
specificity attributed to cargo recruitment receptors30. Figure 1.3 depicts bulk autophagy, specific 
autophagy, and chaperone-mediated autophagy.  
 
 
 
1.2.2 Initiation and General Pathway 
Autophagy begins with nucleation of an isolation membrane (or “phagophore”) which 
can be derived from various sources, such as the plasma membrane, endoplasmic reticulum, 
Golgi complex, or mitochondrial membrane31. The isolation membrane will enclose the target 
particle(s) to create an autophagosome, and subsequently bind to a lysosome, forming an 
Bulk%Autophagy
Specific%Autophagy
CMA%
Autophagosome Autophagolysosome
Lysosomal
Hydrolases
Chaperone%
and%Protein
Figure 1.3 Specificity in Autophagy  
Autophagy can be bulk, specific, or mediated by chaperone proteins201. Images adapted from 
Servier Medical Art by Servier, licensed under CC BY.  
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autolysosome or autophagolysosome, in which the cargo will be degraded32. Autophagy is 
closely linked to endocytosis, a means by which cells absorb extracellular material, and as such, 
an autophagosome may fuse with an endosome to produce an amphisome, which will then fuse 
with a lysosome for degradation32. Several signaling cascades have been reported to regulate 
autophagy. The major control complexes for autophagy are the mammalian target of rapamycin 
(mTOR) and an upstream regulator of mTOR, 5’ adenosine monophosphate-activated protein 
(AMPK), both of which phosphorylate unc-51 like activating kinase I (ULK1) on different 
residues to initiate or repress autophagy respectively33. Ultimately, inputs regarding stress, 
nutrient deprivation, and energy levels converge on the mTOR/AMPK pathways to regulate 
autophagy 33. In the context of these inputs, autophagy is initiated when ULK1 (ATG1) is 
activated, resulting in it phosphorylating ATG13 and FIP200 to create the initiation complex, 
and Beclin 1, which enhances the activity of ATG14L-containing VPS34 complexes, causing 
nucleation34. The newly discovered protein ATG101 has also been shown to phosphorylate 
ATG13 and FIP200 and complex with ATG1335. Two ubiquitin-like conjugation systems are 
also involved in initiation: the first is the ATG12-ATG5 system (which is formed when ATG12 
is activated by ATG7, and transferred to ATG10 before being covalently linked to ATG5, and 
subsequently forming a complex with ATG16)36,37. The second is the  system, in which  (ATG8) 
is cleaved by the protease ATG4B to form LC3-I (which resides in the cytosol), then conjugated 
to phosphatidylethanolamine (PE) by ATG7 and ATG3 to generate LC3-II34,36,38. LC3-II is 
involved in joining cargo to the autophagosome and additionally in the closure of the 
phagophore39. Figure 1.4 depicts mTOR-dependent autophagy.  
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1.2.3 Regulation of Autophagy  
As previously mentioned, inputs regarding starvation, energy availability, and cellular 
stress converge at the AMPK and mTOR pathways, which will in turn activate or repress 
autophagy directly to maintain cellular homeostasis33. Recent studies have also demonstrated the 
existence of mTOR-independent pathways: where 1) ERK-mediated induction of cyclin E 
Figure 1.4 Macroautophagy   
mTOR-dependent autophagy is initiated by inhibition of mTOR, which leads to a complex 
cascade of signaling events which mediate membrane nucleation, elongation, and 
sequestration of cargo33. Illustration reproduced courtesy of Cell Signaling Technology, Inc. 
(www.cellsignal.com) 
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increases cAMP signaling, resulting in enhanced recruitment of Beclin 1 and the formation of 
autophagosomes, and 2) cAMP/EPAC appears to inhibit autophagy by activation of complex 
signaling involving the cAMP-Epac-Rap2B-PLC-ε-IP3 and Ca2+-calpain-Gsα pathways40,41,42,43. 
When initiated by distress, autophagy is believed to be unspecific in the nature of the cargo 
targeted, often called “bulk autophagy” or “cargo independent” autophagy34. Autophagy which is 
tightly regulated to maintain a functional pool of organelles, or remove a specific set of 
organelles during development, is called “selective autophagy” or “cargo-dependent/cargo-
specific autophagy”34. Selective autophagy requires the efficient coordination of autophagosome 
formation and cargo recruitment to effectively clear out organelles – however the sequence in 
which these two events occur has yet to be determined44,29. It is possible that pre-existing 
isolation membranes may be recruited to tagged cargo, or alternatively, the cargo itself may 
signal and induce the formation of an isolation membrane to form around it. Regardless of the 
order, selectivity for substrates is mediated by autophagy receptors which accumulate on the 
surface of the target organelle and directly or indirectly link to the autophagosome30.  
 
1.2.4 Mitophagy   
  As the powerhouse of the cell, mitochondria produce ATP by utilizing the proton motive 
force (Δp) generated by sequential reduction of electrons though the complexes of the electron 
transport chain (ETC)45.  The electron transport chain is a main site of production of reactive 
oxygen species (ROS): highly reactive molecules capable of propagating oxidative chain 
reactions and causing cellular damage46. As a result, a healthy pool of mitochondria must be 
maintained by tight quality control47. In some cell types, mitochondria are removed completely 
during development, and mitophagy serves as the mechanism to achieve this48,49.  
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Programmed mitochondria clearance is well described in the eye lens and in red blood 
cell/reticulocyte maturation48,49. In both cases, the selective clearance of mitochondria appears to 
be stimulated by upregulation of the gene BNIP3L, producing a protein called NIX, which has 
the ability to cause mitochondrial membrane depolarization48,49. Following loss of mitochondrial 
membrane potential, PTEN-induced putative kinase 1 (PINK1) localizes to the outer 
mitochondrial membrane, where it resides in its full-length, active form50. PINK1 phosphorylates 
ubiquitinated proteins on the outer mitochondrial membrane and additionally phosphorylates and 
activates the E3 ubiquitin ligase, Parkin, which then ubiquitinates proteins on the outer 
mitochondrial membrane to become substrates for PINK1, resulting in an amplification of the 
mitophagy signal51,52,53,54,55,56. Finally, the phosphorylated ubiquitin chains will recruit signal 
amplification factors such as tank-binding kinase 1 ( TBK1), and autophagy receptors such as 
neighbor of BRCA1 gene 1 (NBR1), optineurin (OPTN), nuclear dot protein 52 (NDP52), tax1-
binding protein 1 (TAX1BP1), autophagy and Beclin 1 regulator 1 (AMBRA1) and sequestome-
1 (p62) which associate with various autophagosome-associated factors via their -interacting 
regions (LIR) to deliver the autophagy machinery57,58,59,60.  
The above scenario provides an example of ubiquitin-mediated autophagy, a process by 
which poly-ubiquitinated mitochondria are recognized and recruited to the autophagosome via 
autophagy receptors. In addition to induction during specific stages of cell development, 
ubiquitin-mediated autophagy is common to mitochondria which have altered mitochondrial 
membrane potential due to damage. In other cases, autophagy may be receptor-mediated, with a 
specific receptor found on the surface of the mitochondria forming the link to an autophagosomal 
factor via its -interacting region (LIR)59. Some known mitochondrial membrane receptors are 
BCL2/Adenovirus E1B 19kDa Interacting Protein 3 (BNIP3), BCL2/Adenovirus E1B 19kDa 
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Interacting Protein 3-Like (NIX), fun14 domain-containing 1 (FUNDC1) and the phospholipid 
cardiolipin (CL)59. Research in this area continues to explore the specific contexts in which each 
protein recruits the autophagosome, however; evidence suggests the existence of redundancy in 
the system55. Furthermore, many of the factors involved in autophagic recruitment possess 
numerous roles in diverse cellular processes, leading to complexity in the study and targeting of 
autophagy in disease.  
 
1.2.5 Autophagy Defects in AML  
Although a relatively recent discovery, several studies have shown that the loss of 
autophagy genes and reduction in gene products is a characteristic of leukemia. Activation of the 
Akt/mTOR pathway (and thus repression of autophagy) has been shown to be essential for 
leukemia cell propagation61. Mice lacking ATG7 in the hematopoietic system displayed 
increased myeloproliferation which resembled human myelodysplastic syndromes and developed 
into AML62. Similarly, mice lacking FIP200 in the hematopoietic system displayed increased 
myeloproliferation combined with a significant decrease in healthy blood cell maturation63. The 
parallel effects of these studies support the hypothesis that autophagic dysfunction produced 
these phenotypes 64,65,66. AML cells with a mutation in splicing factor U2AF35 (common in both 
AML and MDS patients) have been shown to inefficiently produce the essential autophagy factor 
ATG7 leading to defective autophagy67. The dysfunctional ATG7 pre-mRNA produced by these 
cells was found in primary patient samples with this mutation67. The mitochondrial depolarizing 
factor and autophagy receptor NIX has been shown to be downregulated in high-risk MDS and 
further decreased after disease progression to AML68. A recent in silico analysis of AML showed 
that several autophagy genes are found within chromosomal regions commonly heterozygously 
 13 
deleted in AML, and these deletions were accompanied by decreased expression of mRNA for 
many of these genes69. The same study examined primary patient samples and found decreased 
expression of autophagy genes in the dominant blast cell population compared to the blast 
marker negative population69. With evidence of various autophagy defects in cancer, and a link 
between the genes that regulate autophagy, carcinogenesis, and cell death, it is clear that 
autophagy plays a complex role in cancer. As such, the effect of modulating autophagy now 
holds considerable promise for cancer therapy.  
 
1.2.6 Multiple Roles of Autophagy Proteins  
Adding complexity to an already intricate system, the majority of autophagy-related 
proteins play various autophagy-independent functions in cell signaling and homeostasis70. Of 
specific interest to this study, all three proteins of interest (i.e., ATG7, NIX, and p62) are 
involved in cell death/survival pathways. ATG7, which within the context of autophagy activates 
one of the ubiquitin-like conjugation systems and additionally is involved in conjugating PE to 
LC3-I to form LC3-II, has been shown to modulate p53/TP53 activity to regulate cell cycle and 
survival during metabolic stress71. NIX, which is able to depolarize the mitochondrial membrane 
and acts as a mitophagy receptor, is also known to be an apoptosis inducer and potentially also a 
tumor suppressor72,73. Finally, p62, a mitophagy receptor protein, has been shown regulate cell 
proliferation, tumorigenesis, and act as a signaling hub for apoptosis74,75,76. Indeed, autophagy is 
not the isolated mechanism it was once believed to be; it is inseparably connected to major 
signaling pathways in the cell where it is capable of modulating growth, development, survival 
and death. 
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1.3 Proteins of Interest  
Since an all-encompassing study of autophagy proteins was not feasible, we focused our 
study instead on three autophagy proteins which would serve to exemplify autophagy deficiency 
at two key stages: autophagosome formation (ATG7), and cargo recruitment (p62 and NIX). 
Autophagy protein ATG7  was selected to provide key data on deficiency of all types of 
autophagy, as it is essential for activation of the two ubiquitin-like conjugation systems which 
guide autophagosome formation36. As dysregulated mitochondria are a common feature of AML 
– characterized by increased mitochondrial mass, low mitochondrial spare reserve capacity, and 
a dependence on mitochondrial fatty acid oxidation for cell proliferation – we additionally 
selected two factors involved in mitochondrial autophagy77,78,79. NIX and p62 both serve as 
mitochondrial receptors whereby they guide the recognition and sequestration of mitochondria to 
the autophagosome80,81,82,83,84. These two proteins differ in their mode of attachment and 
sequestration – NIX, found on the mitochondrial membrane, contains an LIR domain allowing 
for linkage to LC3-II found on the autophagosome, while p62 binds to ubiquitin on mitochondria 
(a modification which serves as a tag for degradation), and also links to LC3-II on the 
autophagosome via an LIR domain30,59,85. Figure 1.5 provides a visual depiction of the roles of 
these proteins.  
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Figure 1.5 Roles of Selected Autophagy Proteins in Autophagy 
A) ATG7 plays a role in the conjugation of LC3-I to phosphatidylethanolamine36. B) ATG7 is 
also involved in production of one of the ubiquitin-like conjugation systems which is essential 
for autophagy induction36. C) NIX (box above) is an autophagy receptor found in 
mitochondria which has an LIR domain for binding to LC3-II on the phagophore81. p62 (box 
below) is an autophagy receptor which binds ubiquitinated mitochondria and has an LIR 
domain for binding to LC3-II on the phagophore60,202. Images adapted from Servier Medical 
Art by Servier, licensed under CC BY. 
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Chapter 2: Rationale, Objectives, and Hypothesis 
2.1 Targeting Autophagy in Cancer 
There is currently a pressing need to understand the settings in which autophagy should 
be targeted in order to optimize cancer therapeutics and overcome drug resistance. The paradox 
of autophagy provides two different modulating schemes whereby: 1) upregulation of autophagy 
confers advantage to cells with high metabolic needs or therapy-induced cellular stress by 
recycling unnecessary or dysfunctional cellular components; it would appear best to inhibit 
autophagic activation so that the cells will succumb to the therapy; and 2) activation of 
autophagy permits the clearance of fusion oncoproteins or a reduction in organelles necessary for 
the cell to survive, it would be best to initiate autophagy. Several agents for each class have been 
described and proposed as potential anticancer therapeutics to be used on their own, or in 
combinatorial treatments86.  
Recent studies have indicated that disruption of various homeostatic signaling pathways 
such as mTOR, AMPK, and Akt are potential targets for inducing pro-death autophagy in cancer 
cells87,88,89,90,91,92,93. The addition of the mTOR inhibitor ciclopirox, an antifungal agent, to the 
established preclinical anti-leukemia agent parthenolide, demonstrated greater toxicity against 
AML than either compound independently94. The induction of autophagy through drugs targeting 
AML fusion oncoproteins (e.g. AML1-eight-twenty-one (ETO) targeting drugs) had a pro-
survival effect, however, combined treatment of the AML1-ETO–targeting drugs with the 
mTOR-inhibiting agent chloroquine increased cell death, indicating that autophagy activators 
and inhibitors could even be used as a combinatorial therapy95. Arsenic trioxide (As2O3) inhibits 
cell proliferation in a manner dependent on autophagic induction96,97. To prove the essential 
nature of autophagy in this mechanism, HL60 (human promyelocitic leukemia) cells were treated 
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with the autophagy inhibitor 3-methyladenine (3-MA) after As2O3, which attenuated the cell 
death97. Interestingly, the addition of 3-MA prior to treatment with As2O3 potentiated cell 
death97. These conflicting results ultimately led to the conclusion that autophagy was inhibitory 
in the initiation stage of As2O3-induced apoptosis, however it amplified As2O3-induced apoptosis 
post-initiation, demonstrating the temporal complexity of autophagy-targeting97.  
Given that autophagy may confer survival advantage to cells via recycling of cellular 
components, autophagy inhibitors also show potential as anti-cancer therapeutics86. Indeed, 
Class-III-PI3K inhibitors such as 3-MA, mentioned above, inhibit the formation of 
autophagosomes and have been shown to enhance the effects of various chemotherapy and 
radiation-based treatments98,99,100. The inhibitor of vacuolar ATPase, bafilomycin A1, which 
prevents the fusion of autophagosomes and lysosomes, and autophagosome-degradation inhibitor 
chloroquine have both been shown to increase the cytotoxicity of other anticancer 
medications101,102,103.  
As some cancers have been found to display characteristics similar to dysfunctional 
autophagy systems, understanding the role and modulating potential of autophagy in cancer has 
become a subject of great interest.  While the effects of targeting autophagy in cancer are 
complex, the modulating potential of this pathway provides novel ways to eliminate cancer cells 
and increase the efficacy of other treatments.  
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2.2 Rationale of Study  
This project aimed to explore the relationship between autophagy and AML using genetic 
silencing of autophagy genes ATG7, SQSTM1 and BNIP3L. In particular, we were interested in 
the response of these cells to a panel of drugs with hopes of defining the value of using 
autophagy genes as a marker for tailored chemotherapy with mitochondrial-targeting agents.  
 
2.3 Objectives 
1.   Produce knockdown AML cell lines of genes ATG7, BNIP3L, and SQSTM1, and 
describe changes in mitochondrial phenotype in these cell lines compared to the 
transduced control.  
2.   Characterize the effects of these autophagy deficiencies on chemotherapy efficacy using 
DNA-targeting and mitochondrial-targeting drugs.  	  
2.4 Hypothesis  
AML cell lines with knockdown in autophagy genes ATG7, BNIP3L, or SQSTM1 will 
accumulate mitochondrial dysfunctions resulting in increased sensitivity to mitochondrial-
targeting drugs, but not DNA-targeting drugs compared to the transduced control AML cell line.  
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Chapter 3: Materials and Methods 
3.1 Cell Culture 
3.1.1 Growth Media  
Acute myeloid leukemia (OCI-AML2) cell lines were cultured in Iscove’s Modified 
Dulbecco’s Medium (IMDM; Fischer Scientific, Grand Island, NY) supplemented with 10% 
fetal bovine serum (FBS; Sigma, St. Louis, MO) and 2% penicillin-streptomycin (Sigma, 
Product of USA). All cell lines were grown in T25 or T75 vented filter cap tissue culture flasks 
(Sarstedt, Product of Germany) and incubated in a humidified air atmosphere containing 5% CO2 
at 37°C.  
 
3.1.2 Lentiviral Transduction to Produce Knockdown Cell lines  
OCI-AML2 cells were brought to a concentration of 5 x 106 cells/mL, spun down, and re-
suspended in 6.5 mL of media containing protamine sulphate (5 µg/mL), 1 mL of virus cocktail 
(containing virus carrying the short hairpin RNA (shRNA) sequence and a gene for puromycin 
resistance). Following incubation overnight at 37°C, the cells were centrifuged and then washed 
and re-suspended in fresh puromycin media (1 ug/mL). Subsequent culturing of these cells was 
done with 1 ug/mL puromycin to maintain knockdown. A shRNA scramble sequence was used 
to produce the transduced control (TRC) cell line. The shRNA coding sequences are shown in 
table 3.1. 
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Table 3.1 shRNA Coding Sequences for Lentiviral Transfection 
Gene ID Vector #  (Sigma-Aldrich) shRNA Coding Sequence (5’-3’) 
ATG7 #6 TRCN0000007588 CCGGCCAAGGTCAAAGGACGAAGATCTCGAGATCTTCGTCCTTTGACCTTGGTTTTT 
 
ATG7 #9 TRCN0000007586 CCGGGCTTTGGGATTTGACACATTTCTCGAGAAATGTGTCAAATCCCAAAGCTTTTT 
BNIP3L 
(NIX) 
 
#1 TRCN0000298517 CCGGTATTGTCACAGTAGCTTATTTCTCGAGAAATAAGCTACTGTGACAATATTTTTG 
BNIP3L 
(NIX) #3 TRCN0000007846 CCGGGCTAGGCATCTATATTGGAAACTCGAGTTTCCAATATAGATGCCTAGCTTTTT 
BNIP3L 
(NIX) 
 
#5 TRCN0000007847 
CCGGCAGTCAGAAGAAGAAGTTGTACTCGAGTACAACTTCTTCTTCTGACTGTTTTT 
 
SQSTM1 
(p62) #11 TRCN00000435931 CCGGTGCCTAATGGCTTTCACTTTCCTCGAGGAAAGTGAAAGCCATTAGGCATTTTTTG 
SQSTM1 
(p62) 
#12 
 
TRCN00000431509 CCGGGAGGATCCGAGTGTGAATTTCCTCGAGGAAATTCACACTCGGATCCTCTTTTTTG 
Scramble 
Control TRC TRCN0000007847  CCGGCAGTCAGAAGAAGAAGTTGTACTCGAGTACAACTTCTTCTTCTGACTGTTTTT 
 
3.2 Growth and Size Analysis  
3.2.1 Cell Counting  
Cells were counted approximately every other day (during scheduled cell replication 
analysis; every day) using a hemocytometer. To enumerate the cells, cells were diluted in 10x 
Trypan Blue stain (Gibco by Life Technologies, Grand Island, NY) at a 1:1 ratio, and 10 µL of 
this mixture was loaded onto the hemocytometer. The number of cells in adjacent sections was 
counted, added, and multiplied by 106 to obtain the cells/mL concentration. 
 
3.2.2 Cell Size Analysis  
Average cell size for each cell line was determined in triplicate on separate days using the 
Multisizer 4 Particle Analyzer (Beckman Coulter). Approximately 1 x 105 – 1 x 106 cells were 
diluted 1:20 in PBS (to a final volume of 10 mL) and then loaded into the machine for average 
cell size determination.   
 
3.2.3 Colony Growth Formation Assay  
Colony growth formation assays determine the ability of a cell to proliferate indefinitely, 
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thereby producing a large colony or clone. In this assay, 103 cells were added to 3 ml of 
MethoCult GF H4434 medium (StemCell Technologies) containing 30% FCS, 1% BSA, 1% 
methylcellulose in IMDM, 10 ng/mL recombinant human IL-3, 3U/mL recombinant human 
erythropoietin, 10-4 M 2-mercaptoethanol (2ME), 2mM L-glutamine, 50 ng/mL recombinant 
human stem cell factor, 10 ng/mL recombinant human granulocyte macrophage-colony 
stimulating factor. Cells in this medium were plated at 1.1 mL per 35mm dish (in duplicate) 
using a blunt-tip syringe. Duplicate dishes were kept alongside a dish containing only distilled 
water (humidity control), within a single 100 mm Petri dish. The plates were then incubated at 
37°C for one to two weeks, after which time the number of colonies was enumerated. A colony 
is defined as a cluster of 50 or more cells104.  
 
3.3 Quantitative PCR 
3.3.1 Sample Preparation and Analysis    
Genomic DNA samples were isolated using the Purelink Genomic DNA Mini Kit 
(Invitrogen, Product of USA) according to the manufacturer protocol (eluted with 150 µL elution 
buffer). The concentration of gDNA was measured using a Nanodrop 200c at 260nm (Thermo 
Scientific). Quantitative PCR was performed in triplicate on a 96-well plate probing for the 
mitochondrial gene NADH dehydrogenase 1 (ND1) alongside the nuclear control gene beta 
globin (HBB). To each well, 10 µL Maxima SYBR Green/ROX qPCR Master Mix (Thermo 
Scientific), 6 µL Nuclease-free water (Thermo Scientific), 1 µL PrimePCR Assay HBB, Hsa 
(Bio-Ra; Product of USA), or 1 µL PrimePCR Assay MT-ND1, Hsa (Bio-Rad; Product of USA) 
and 3 µL of 25 ng/ µL template DNA was added. For negative controls, 3 µL of nuclease-free 
water was added instead of DNA template. For positive controls, 3 µL of PrimePCR Template 
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(Bio-Rad) was added instead of DNA template. The qPCR assay was run on the StepOnePlus 
Real-Time PCR System (Applied Bioscience). Initial gDNA content was determined using the 
ΔΔCT method105.  
 
3.4 Cell Stress Analysis  
3.4.1 Serum Starvation  
Cells were grown up to approximately 1.5 x106 cells/mL in 50 mL of media over the 
course of 3 days. On the day of the assay, the cells were spun down at 1200 RPM for 5 minutes 
and re-suspended in Hank’s buffered saline solution (HBSS; Fischer Scientific, Grand Island, 
NY) to starve the cells. Samples of 7 mL were removed and centrifuged (1200 RPM x 5 minutes) 
at set time intervals (0, 5, 10, 30, 60, 90, 120 minutes) following the switch into HBSS. The 
samples were then re-suspended in 500 mL PBS and transferred into a 1.5 mL Eppendorf tube 
before centrifuging again for 1 minute at 13.2 x 103 RPM, after which the PBS was removed and 
the pellet frozen for future lysis. Proteins Beclin 1, ATG7, , NIX, and p62 were selected to 
provide key information on the process of autophagy at various atages (initiation, elongation, and 
recruitment, respectively). Information pertaining to Western blotting (protein size, antibody 
concentrations, etc.) is found in section 3.5, table 3.2.   
 
3.5 Western Blotting 
3.5.1 Protein Collection  
Cells were collected as a pellet following centrifugation at 1200 RPM, washed with cold 
PBS, and then lysed with a 2:1 ratio of cold Radioimmunoprecipitation assay (RIPA) buffer 
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(Sigma-Aldrich; St. Louis, MO) for 20 minutes on ice. The cells were then centrifuged at 1.32 x 
104
 
RPM for 20 minutes at 4°C and the supernatant was collected.   
3.5.2 BSA/BCA Assay  
The total protein content of the supernatant was quantified using the BCA protein assay, 
in which a set of standards of BSA (Sigma-Aldrich, Product of USA) diluted in distilled water at 
0, 20, 40, 60, 80, and 100 mg/ mL were compared against the acquired protein samples (diluted 
tenfold). The standards and samples were plated on a 96-well plate, and to each well, 200 µL of 
bicinchoinic acid (BCA) working reagent was added (containing 50 parts BCA to one-part 
copper II sulphate (Sigma Aldrich). The optical density was measured at 527 nm using the 
SpectraMax Pro M5 spectrophotometer and SoftMax V5 software. Samples were then prepared 
to contain 30 µg of total protein with 1/6 sample buffer volume (50% w/v sucrose, 7.5% w/v 
SDS, 62.5 mM Tris-HCl at pH 6.8, 2 mM EDTA at pH 7, 3.1% w/v DTT (DL-Dithiothreiol), 
0.01% bromophenol blue) and topped to 30 µL with extra RIPA buffer. The prepared samples 
were stored in an -80°C freezer.  
 
3.5.3 SDS-PAGE and Immunoblotting  
Proteins were separated by size using sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE). Samples were boiled at 95°C for five minutes to denature the 
protein, after which 20 µL of the samples were loaded into the wells of a 10-12% polyacrylamide 
gel and run at 150 V on a Mini Trans-Blot Cell (Bio-Rad) containing electrophoresis buffer (25 
mM Tris base, 190 mM glycine, 3.5 mM sodium dodecyl sulphate) until the loading dye reached 
the bottom of the cell (45 minutes-1 hour). Proteins were transferred from the gel to a polyvinyl 
difluoride (PVDF) membrane (Bio-Rad) in transfer buffer (25 mM Tris base, 190 mM glycine, 
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20% v/v methanol) using a Trans-Blot semi-dry transfer cell set to 25V for 45 minutes. 
Membranes were blocked in 5% BSA (Sigma-Aldrich; St. Louis, MO) in Tris-buffered saline 
(TBS-T: 20 mM Tris base (TBS) plus 0.1% Tween) for 1 hour at room temperature on a rocker, 
followed by two rinse washes and a 5 minute rocker wash with TBS-T. Blocking was followed 
by incubation with the desired primary antibody in 5% BSA-TBST overnight on a rocker at 4°C. 
Membranes were then subjected to two rinse washes, a 15-minute rocker wash, and three 5-
minute rocker washes with TBST. Afterwards, the membrane was incubated with the appropriate 
secondary antibody in 5% BSA-TBST for 1 hour at room temperature on a rocker. Following 
this, membranes were rinsed twice, then washed for 15 minutes and five 5-minute rocker washes 
with TBST. Membranes were incubated for five minutes in Clarity Western ECL Substrate (Bio-
Rad, Product of USA), and promptly transferred (via a plastic sleeve) to the Kodak 4000MM Pro 
Imaging Station (using Kodak Molecular Imaging Software) for visualization of the proteins. 
Relative levels of luminescence were assessed by region of interest (ROI) markers and compared 
to a control protein. Proteins of interest are shown in Table 3.2 below.  
Table 3.2 Proteins of Interest for Western Blotting  
Primary Antibody Isotype Molecular 
Weight (kDa) 
Dilution Catalog Code Manufacturer 
NIX Rabbit 38, 76 1:700 D4R4B Cell Signaling 
P62 Rabbit 60 1:1000 5114 Cell Signaling 
Beclin 1 Rabbit 60 1:1000 D40C5 Cell Signaling 
ATG7 Rabbit 78 1:1000 D12B11 Cell Signaling 
 Rabbit 14,16 1:300 D11 XP (R) Cell Signaling 
GAPDH (Control) Mouse (Conj.) 37 1:15000 GA1R Thermo Scientific 
α-tubulin (Control)  Mouse 55 1:1000 TU-02: sc 8035 Santa Cruz Biotechnology 
 
3.6 Flow Cytometry  
3.6.1 Cell Staining for Analysis of Mitochondrial Health  
Cells were plated in triplicates on a 96-well flat bottom plate (Sarsedt, Product of 
Germany) at 2 x 105 cells/well and then centrifuged at 1200 RPM on a plate spinner for five 
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minutes, allowing for removal of media. Cells were re-suspended in 200 µL of a dye-PBS 
mixture at a given concentration (see table 3.3) and incubated at 37°C for 20 minutes. Following 
incubation, the cells were centrifuged at 1200 RPM on a plate spinner for 5 minutes and re-
suspended in 200 µL PBS/ well. The plate was then placed in the Guava easyCyte 8HT Bench 
Top Flow Cytometer (Millipore) using GuavaSoft 3.1.1 (Millipore) flow cytometry software., set 
to acquire 5000 events per well.  
Four fluorescent dyes were chosen to probe for various elements of mitochondrial health: 
DHE, H2DCFDA, Rho 123, and NAO. The first, dihydroethidium (DHE), is a cell-permeant dye 
which is oxidized by the ROS superoxide (O2·−) to generate a fluorescent product106. The second, 
dihydrodichlorofluorescein diacetate (H2DCFDA), is a dye which undergoes two-electron 
oxidation in the presence of peroxides (notably:  hydrogen peroxide (H2O2) produced by a 
variety of oxidase enzymes) and other ROS such as nitrate and hypochlorous acid to generate the 
fluorescent product 2’, 7’ dichlorodihydrofluorescein (DCF)107. Importantly, H2O2-dependent 
oxidation of H2DCF is dependent on ferrous iron (as found in cytochrome c)108. H2DCF is 
unable to react directly with superoxide109–111. The third, NAO binds to cardiolipin, a component 
of the inner mitochondrial membrane, giving an approximate quantitative measure of 
mitochondrial mass 112. Finally, the fourth dye, Rho 123, is a cationic dye readily sequestered by 
mitochondria in a relationship proportional to the negative (hyperpolarized) mitochondrial 
membrane potential 113. In all analyses, a spherical marker was used to exclude debris and dying 
cells from the forward vs side scatter plots, as apoptosis is associated with increased ROS and 
altered membrane potentials114.  Table 3.3 provides pertinent information relating to flow 
cytometry analysis.  
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Table 3.3 Concentrations of Fluorescent Dyes Used as Mitochondrial Health Probes   
Dye Concentration 
Per Well (diluted 
in PBS) (uM) 
Excitation/ 
Emission 
Channel Used 
for Probe 
Manufacturer  
NAO 0.35 uM 518/530112 Green Enzo Life Sciences 
Rhodamine 123 0.6 uM 507/529115 Green Enzo Life Sciences 
DHE 3 uM 518/605116 Yellow Sigma-Aldrich 
DCF 0.15 uM 490/520116 Green Sigma-Aldrich 
 
3.6.2 Dose-Response Analysis and Propidium Iodide Staining for Measuring Cell Viability  
In order to produce dose response curves, cells were plated in triplicate on a 96-well flat-
bottom plate at 1.8 x 105 cells/well in 95 µL of new media. To this, 5 µL of drug was added to 
produce the desired final concentration, after which the remaining wells on the plate (outer 
edges) were filled to 100 µL with PBS, the plate was wrapped with saran wrap, and incubated in 
a humidified air atmosphere containing 5% CO2 at 37°C for 72 hours (3 days). Table 3.4 
provides information relating to the drugs used in the dose-response. 
Table 3.4 Drugs, Solvents, and Manufacturer Data 
Drug Solvent Manufacturer 
Avocatin B DMSO Microsource  
Cytarabine H2O  Tocris Bioscience 
Daunorubicin H2O Tocris Bioscience  
Doxorubicin H2O Sigma-Aldrich 
FCCP ( Carbonyl cyanide 4 
(trifluoromethoxy)phenylhydrazone) 
DMSO Sigma-Aldrich  
Oligomycin DMSO EMD Chemicals 
Rapamycin DMSO Tocris Bioscience  
Rotenone DMSO Millipore  
Tigecycline  DMSO Sigma-Aldrich 
 
The mechanisms of these drugs are as follows:  1.   Cytarabine	  is	  an	  antimetabolite	  drug	  which	  interferes	  with	  DNA	  synthesis	  by	  combining	  a	  cytosine	  base	  with	  arabinose	  instead	  of	  deoxyribose15	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2.   Doxorubicin	  and	  daunorubicin	  are	  anthracyclines	  which	  impart	  their	  activity	  by	  intercalating	  with	  DNA	  and	  subsequently	  inhibiting	  the	  progression	  of	  DNA	  topoisomerase	  II16.	  3.   Avocatin	  B	  is	  an	  inhibitor	  of	  fatty	  acid	  oxidation	  that	  accumulates	  in	  the	  mitochondria	  117,118.	  	  4.   FCCP	  is	  a	  protonionophore	  and	  uncoupler	  of	  oxidative	  phosphorylation,	  which	  exerts	  its	  effects	  by	  dissipating	  the	  mitochondrial	  membrane	  potential,	  leading	  to	  ATP	  depletion	  and	  increased	  ROS	  production119.	  	  5.   Oligomycin	  is	  an	  ATP	  synthase	  inhibitor	  which	  acts	  by	  blocking	  the	  proton	  channel	  necessary	  for	  the	  oxidative	  phosphorylation	  of	  ADP	  to	  ATP.	  As	  a	  result,	  movement	  of	  the	  electron	  transport	  chain	  is	  greatly	  reduced,	  leading	  to	  mitochondrial	  destabilization	  and	  ultimately	  cell	  death120,121.	  	  6.   Rapamycin	  is	  an	  inhibitor	  of	  mTOR	  complex	  1122.	  	  7.   Rotenone	  is	  an	  electron	  transport	  chain	  (ETC)	  inhibitor	  which	  acts	  by	  blocking	  the	  ETC	  between	  NADH	  dehydrogenase	  (complex	  I)	  and	  CoQ,	  thereby	  blocking	  the	  formation	  of	  the	  proton	  motive	  force	  (PMF)	  required	  for	  the	  oxidative	  phosphorylation	  of	  ADP	  to	  ATP.	  Again,	  movement	  of	  the	  electron	  transport	  chain	  is	  halted,	  leading	  to	  mitochondrial	  destabilization	  and	  consequently	  cell	  death123,124.	  	  8.   Tigecycline	  is	  an	  inhibitor	  of	  mitochondrial	  translation	  and	  inhibitor	  of	  mitochondrial	  function77.	  	  
 
Propidium iodide is a DNA intercalating agent that is only able to permeate dead cells125. As 
a result, it is commonly used to quantify the dead cells in a population. Following incubation, 
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cells were re-suspended in buffered PI (1% PI (Biovision), 2% BSA in PBS), and read 
immediately on the Guava easyCyte 8HT Bench Top Flow Cytometer (Millipore) using 
GuavaSoft 3.1.1 (Millipore) flow cytometry software at 2500 events/ well.  
3.7 Statistical Analyses  
3.7.1 One-Way ANOVA and Dunnett Multiple Comparisons Test  
A one-way analysis of variance (ANOVA) is a statistical technique used to identify 
significant differentces within a set of measurements126. This analysis tests the null hypothesis 
that samples from two or more groups have have the same mean values126. The null hypothesis is 
rejected if the computed p value is smaller than the significance level: α126. For our purposes, we 
used α =0.05. Dunnett’s multiple comparisons test is a followup to ANOVA which compares 
every mean to the control mean – in our case, the transduced control: TRC127. This test allows 
for computation of multiplicity-adjusted p values – i.e the smallest significance level applied to 
the family of comparisons at which the comparison of interest will be deemed statistically 
significant128. One-way ANOVA and Dunnett’s tests were performed using Graphpad Prism 6.0 
Software (Graphpad Software Inc.).  
 
3.7.2 Unpaired T-Tests  
T-tests are similar to the one-way ANOVA in their goal of identifying significant 
differences, however they only compare two data sets126. T-tests compute p values which are 
compared to the chosen significance level (α =0.05) to determine if the null hypothesis should be 
accepted or rejected126. T-tests were performed using Graphpad Prism 6.0 Software (Graphpad 
Software Inc.). 
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Chapter 4: Results 
4.1 Confirmation of knockdown 
Western blot analysis of protein expression was performed to assess gene knockdown for 
the NIX, ATG7, and SQ cell lines. Band intensity of each protein was compared and normalized 
to the loading control, GAPDH, as shown in figures 4.1 A-C. TRC represents the transduced 
scramble control cell line.  
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Figure 4.1A shRNA Knockdown of Autophagy Gene BNIP3L 
 Autophagy gene BNIP3L (protein: NIX, cell line IDs: NIX1, NIX3, NIX5) was successfully 
knocked down by lentiviral mediated shRNA and confirmed by immunoblotting. 
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Figure 4.1B shRNA Knockdown of Autophagy Gene SQSTM1  
Autophagy gene SQSTM1 (protein: p62, cell line IDs: SQ11, SQ12) was successfully 
knocked down by lentiviral mediated shRNA and confirmed by immunoblotting. 
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As shown in figures 4.1 A-C, all three genes were successfully knocked down. NIX 
protein expression was reduced to 10-30% of TRC levels, p62 protein expression was reduced to 
40-50% of TRC levels and ATG7 protein expression was reduced to 40-50% of TRC levels. 
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Figure 4.1C shRNA Knockdown of Autophagy Gene ATG7 
Autophagy gene ATG7 (protein: ATG7, cell line IDs: ATG7 6, ATG7 9) was successfully 
knocked down by lentiviral mediated shRNA and confirmed by immunoblotting. 
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4.2 Cell Proliferation Assay  
Viable cells were enumerated over the course of 3-4 days to assess the effects of gene 
knockdown on cell proliferation. Data was normalized to the previous day to give the population 
doubling (PD) per 24 hour period as shown in the equation below129.  
𝑃𝐷 = 	  𝐶𝑜𝑢𝑛𝑡	  𝑜𝑛	  𝐷𝑎𝑦	  2𝐶𝑜𝑢𝑛𝑡	  𝑜𝑛	  𝐷𝑎𝑦	  1 
The data was then normalized to the starting population doubling value. Population doubling 
data is shown in figures 4.2 A- C for the NIX, SQ, and ATG7 cell lines respectively.  
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Figure 4.2A Cell Proliferation for the NIX (BNIP3L KD) Cell Lines Measured by Daily 
Cell Counts 
Two non-consecutive data sets are displayed. Arrows indicate the starting population 
doubling value to which subsequent values are normalized.  
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Figure 4.2B Cell Proliferation for the SQ (SQSTM1 KD) Cell Lines Measured by Daily 
Cell Counts 
Two non-consecutive data sets are displayed. Arrows indicate the starting population doubling 
value to which subsequent values are normalized.  
 
Figure 4.2C Cell Proliferation for the ATG7 (ATG7 KD) Cell Lines Measured by Daily 
Cell Counts  
Two non-consecutive data sets are displayed. Arrows indicate the starting population doubling 
value to which subsequent values are normalized.  
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As shown in figures 4.2 A-C, cell proliferation was altered as a result of autophagy gene 
knockdown. Unlike the TRC cell line, for which proliferation increased over the count days in a 
stepwise manner, most knockdown cell lines either showed decreased proliferation or bi-
directional changes in proliferation rate.  
 
4.3 Cell Size Measurements 
Cell size was measured using the Multisizer 4 Particle Analyzer (Beckman Coulter). 
Mean cell size values were obtained in triplicate. Averaged triplicate values are shown in figures 
4.3 A-C for the NIX, p62, and ATG7 cell lines.   
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Figure 4.3A Cell Size Measurements for the NIX (BNIP3L KD) Cell Lines 
Average cell size was measured in triplicate with n=3. 
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Figure 4.3B Cell Size Measurements for the SQ (SQSTM1 KD) Cell Lines 
Average cell size was measured in triplicate with n=5. 
 
Figure 4.3C Cell Size Measurements for the ATG7 (ATG7 KD) Cell Lines 
Average cell size was measured in triplicate with n=4. 
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As shown in figures 4.3 A-C, average cell size did not change with autophagy gene 
knockdown.  A one-way ANOVA with a Dunnett’s multiple comparisons test confirmed these 
changes to be statistically insignificant compared to TRC (ns p>0.05). The multiplicity adjusted 
p values are shown in table 4.1.  
 
 
Cell Line  Multiplicity adjusted p value  
NIX1  F8=2.644; p=0.0709 
NIX3 F8=2.621; p=0.0734 
NIX5 F8=1.454; p=0.3847 
SQ11 F12=1.165; p=0.4252 
SQ12 F12=0.1170; p=0.9900 
ATG7 6  F9=0.5009; p=0.8378 
ATG7 9 F9=0.2810; p=0.9443 
 
 
4.4 Colony Formation  
Colony formation assays were also completed in triplicate for one knockdown cell line 
for each knockdown group. Colonies were grown in MethoCult GF H4434 medium for a period 
of 1 week at which time they were enumerated manually using a microscope. The number of 
colonies per dish set were averaged to get the colony count per dish. Triplicate measures were 
averaged and are shown in figures 4.4 A-C.  
 
Table 4.1 Multiplicity Adjusted P Values for Cell Size Measurements  
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Figure 4.4A Colony Growth Formation for the NIX1 (BNIP3L KD) Cell Line  
Average number of colonies grown in a one-week period was measured in triplicate. One 
TRC data point was rejected as an outlier after performing Grubb’s test (p<0.05).  
ns p>0.05, *p£0.05 
 39 
 
B"""""""""
TRC SQ11
0
25
50
75
100
125
150
175
C
ol
on
ie
s 
Pe
r D
is
h
Figure 4.4B Colony Growth Formation for the SQ11 (SQSTM1 KD) Cell Line  
Average number of colonies grown in a one-week period was measured in triplicate. One 
TRC data point was rejected as an outlier after performing Grubb’s test (p<0.05).  
ns p>0.05 
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Unpaired T-tests confirmed a statistically significant decrease in colony formation for the 
NIX1 cell line (F3=3.538; p=0.0384), but not the SQ11 (F3=0.6854; p=5423) or ATG7 
(F3=1.614; p=0.2049) cell lines when compared to TRC (ns p>0.05, *p£0.05).  
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Figure 4.4C Colony Growth Formation for the ATG7 9 (ATG7 KD) Cell Line  
Average number of colonies grown in a one-week period was measured in triplicate. One 
TRC data point was rejected as an outlier after performing Grubb’s test (p<0.05).  
ns p>0.05 
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4.5 Fluorescent Dyes as Probes for Mitochondrial Health 
Fluorescence levels of DHE, DCF, and Rho 123 were measured using a Guavasoft flow 
cytometer to provide an assessment of superoxide levels. A single-assay representative graph of 
each triplicate measure is presented in figure 4.5A. Each measurement is normalized to the TRC 
cell line.   
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Figure 4.5A Measuring Markers of Mitochondrial Health: Dihydroethidium (DHE) 
DHE levels are increased in almost all knockdowns indicating increased superoxide. Outliers 
in each measurement were rejected according to Grubb’s test (p<0.05). 
ns p>0.05, *p£0.05, **p£0.01, ***p£0.001, ****p£0.0001 
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Fluorescence levels of DCF were measured using a Guavasoft flow cytometer to provide 
an assessment of peroxide and other ROS levels. A single-assay representative graph of each 
triplicate measure is presented in figure 4.5B. Each measurement is normalized to the TRC cell 
line. 
 
BNIIP3L'KDs!
ATG7'KDs!
SQSTM1'KDs!
TRC1 NIX1 NIX3 NIX5
0.0
0.5
1.0
1.5
N
or
m
al
iz
ed
 M
ea
n 
Fl
uo
re
sc
en
ce
DCF
*
*
TRC1 ATG7 6 ATG7 9
0.0
0.5
1.0
1.5
N
or
m
al
iz
ed
 M
ea
n 
Fl
uo
re
sc
en
ce
DCF
*** ***
TRC1 SQ11 SQ12
0.0
0.5
1.0
1.5
N
or
m
al
iz
ed
 M
ea
n 
Fl
uo
re
sc
en
ce
DCF
**
****
B'''''''''
Figure 4.5B Measuring Markers of Mitochondrial Health: Dichlorofluorescein (DCF) 
DCF levels are decreased in almost all knockdowns indicating decreased levels of peroxide 
and other ROS. Outliers in each measurement were rejected according to Grubb’s test 
(p<0.05). 
ns p>0.05, *p£0.05, **p£0.01, ***p£0.001, ****p£0.0001 
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Fluorescence levels of Rho 123 were measured using a Guavasoft flow cytometer to 
provide an assessment of the mitochondrial membrane potential. A single-assay representative 
graph of each triplicate measure is presented in figure 4.5C. Each measurement is normalized to 
the TRC cell line. 
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Figure 4.5C Measuring Markers of Mitochondrial Function: Rhodamine 123 (Rho 123) 
Rho 123 levels are increased in almost all knockdowns indicating a hyperpolarized 
mitochondrial membrane potential. Outliers in each measurement were rejected according to 
Grubb’s test (p<0.05). 
ns p>0.05, *p£0.05, **p£0.01, ***p£0.001, ****p£0.0001 
 44 
As shown in figures 4.5A-D, mean fluorescence of DHE was increased in all KD cell 
lines, indicating increases in the ROS superoxide106. DCF was decreased in all KD cell lines, 
indicating decreases in the ROS associated with this dye, which is particularly sensitive to 
hydrogen peroxide107. Levels of Rho 123 were increased in all KD lines indicating 
hyperpolarization of the mitochondrial membrane potential113. A one-way ANOVA with a 
Dunnett’s multiple comparisons test was used to compare the mean of each knockdown to the 
mean of TRC (ns p>0.05, *p£0.05, **p£0.01, ***p£0.001, ****p£0.0001). Table 4.2 provides 
the multiplicity adjusted p values associated with each measurement. 
 
 
Cell Line  DHE DCF Rho 123 
NIX1 F8=10.12; p<0.0001 F8=2.313; p=0.1159 F8=9.455; p<0.0001 
NIX3 F8=19.46; p<0.0001 F8=2.892; p=0.0491 F8=21.97; p<0.0001 
NIX5 F8=26.78; p<0.0001 F8=3.065; p=0.0380 F8=19.96; p<0.0001 
SQ11 F6=11.95; p<0.0001 F6=6.410; p=0.0012 F6=7.087; p=0.0007 
SQ12 F6=13.09; p<0.0001 F6=11.07; p<0.0001 F6=6.880; p=0.0008 
ATG7 6 F6=2.215; p=0.1168 F6=7.879; p=0.0004 F6=21.20; p<0.0001 
ATG7 9 F6=5.756; p=0.0022 F6=7.490; p=0.0006 F6=8.291; p=0.0003 
 
 
4.6 Measures of Mitochondrial Quantity  
 
Fluorescence levels of NAO were measured using a Guavasoft flow cytometer to provide 
an assessment of the quantity of mitochondria in the cell population. A single-assay 
representative graph of each triplicate measure is presented in figure 4.6A. Each measurement is 
normalized to the TRC cell line.  
Table 4.2 Multiplicity Adjusted P Values for DHE, DCF, and Rho 123 Measurements 
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Figure 4.6A Measuring Markers of Mitochondrial Quantity: Nonyl Acridine Orange 
(NAO) 
NAO levels were not significantly changed in the knockdowns indicating no overall effect on 
mitochondrial quantity.  Outliers in each measurement were rejected according to Grubb’s test 
(p<0.05). 
ns p>0.05, *p£0.05, **p£0.01, ***p£0.001, ****p£0.0001 
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As shown in figures 4.6A, mean fluorescence of NAO was not significantly altered in all 
KD cell lines, indicating no overall effect on mitochondrial quantity106. A one-way ANOVA 
with a Dunnett’s multiple comparisons test was used to compare the mean of each knockdown to 
the mean of TRC (ns p>0.05, *p£0.05, **p£0.01, ***p£0.001, ****p£0.0001). Table 4.3 
provides the multiplicity adjusted p values associated with each measurement. 
 
 
Cell Line  NAO 
NIX1 F7=1.224; p=0.5123 
NIX3 F7=0.2387; p=0.9899 
NIX5 F7=0.06940; p=0.9997 
SQ11 F6=1.313; p=0.3762 
SQ12 F6=0.07597; p=0.9958 
ATG7 6 F5=0.4213; p=0.8824 
ATG7 9 F5=0.5856; p=0.7914 
 
 
 
 
Quantitative (real-time) PCR was used to assess the relative concentration of 
mitochondrial gene ND1 in order to estimate the quantity of mitochondria in the cell population. 
The results were analyzed using LinRegPCR software and the starting quantity of mtDNA was 
determined using the ΔΔCT method The results, normalized to TRC are shown in figure 4.6B.  
Table 4.3 Multiplicity Adjusted P values for NAO Measurements 
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Figure 4.6B qPCR Estimation of Relative mtDNA Copy Number 
(A) NIX (B) SQ and (C) ATG7 cell lines were probed for the quantity of mitochondrial gene 
ND1 relative to the nuclear gene HBB. All results are normalized to TRC. For NIX n=4, p62 
n=4, and ATG7 n=3. A Grubb’s outlier test was performed to identify any outliers in the data. 
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As shown in figure 4.6B, mtDNA copy number undergoes significant flux over the 
course of the measurements for both the KDs and control line. A one-way ANOVA with a 
Dunnett’s multiple comparisons test was used to compare the mean of each knockdown to the 
mean of TRC and showed that these changes were statistically insignificant  (ns p>0.05). Table 
4.4 provides the multiplicity adjusted p values associated with each measurement. 
 
Cell Line Multiplicity adjusted p values  
NIX1 F12=0.06205; p=0.9999 
NIX3 F12=0.003193; p=>0.9999 
NIX5 F12=2.677 p=0.0506 
SQ11 F9=0.6128; p=0.7710 
SQ12 F9=1.133; p=0.4506 
ATG7 6 F5=2.045; p=0.1601 
ATG7 9 F5=0.4249; p=0.8806 
 
 
4.7 Serum Starvation  
Serum starvation was run for one cell line for each knockdown group. These were the 
NIX5, SQ11, and ATG7 9 cell lines, chosen based on the best knockdown from the most recent 
Western blot the assay. We selected the proteins Beclin1 and ATG7 for analysis of early 
autophagy, as both play important roles in initiation22. Since conversion of LC3-I to LC3-II 
results in recruitment to the autophagosomal membrane, and LC3-II is degraded along with the 
contents of the autophagosome, monitoring LC3-I and LC3-II levels provides an excellent 
measure of autophagy flux39. Finally, to analyze late autophagy at the point of cargo recruitment, 
we selected the mitochondrial receptors NIX and p6259. Levels of autophagy proteins Beclin 1, 
ATG7, LC3-I, LC3-II,  NIX, and p62 were measured by Western blotting, and normalized to the 
transduced control (TRC) cell line to provide data on key stages of autophagy. The results of the 
serum starvation assay are shown in figure 4.7 A-E.  
Table 4.4 Multiplicity Adjusted P Values for mtDNA Measurements 
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Figure 4.7A Serum Starvation Results – Probing for Upstream and Downstream 
Autophagy Proteins  
The TRC, NIX5 (BNIP3L KD), SQ11 (SQSTM1 KD), and ATG7 9 (ATG7 KD) cell lines 
were probed for the autophagy protein Beclin 1 following serum starvation by Western 
blotting. Graphed results are normalized to TRC values.     
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Figure 4.7B Serum Starvation Results – Probing for Upstream and Downstream 
Autophagy Proteins  
The TRC, NIX5 (BNIP3L KD), and SQ11 (SQSTM1 KD) cell lines were probed for the 
autophagy protein ATG7 following serum starvation by Western blotting. Graphed results are 
normalized to TRC values. 
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Figure 4.7C Serum Starvation Results – Probing for Upstream and Downstream 
Autophagy Proteins  
The TRC, NIX5 (BNIP3L KD), SQ11 (SQSTM1 KD), and ATG7 9 (ATG7 KD) cell lines 
were probed for the autophagy proteins LC3-I and LC3-II following serum starvation by 
Western blotting. Graphed results are normalized to TRC values.  
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Figure 4.7D Serum Starvation Results – Probing for Upstream and Downstream 
Autophagy Proteins  
The TRC, SQ11 (SQSTM1 KD), and ATG7 9 (ATG7 KD) cell lines were probed for the 
autophagy protein NIX following serum starvation by Western blotting. Graphed results are 
normalized to TRC values.  
 53 
 
 
0""""""""5"""""""10"""""30""""""60""""""90"""""120""min
E)#Probing# for#p62#Protein
TRC
p62$
GAPDH
ATG7%KD%Cell%
Line%(ATG7%9)
p62
!!tubulin
BNIP3L KD#Cell#
Line (NIX5)
p62
GAPDH
0 5 10 30 60 90 120
0.0
0.5
1.0
1.5
2.0
Time (Minutes)
[A
U
]
ATG7 9 Cell Line
0 5 10 30 60 90 120
0
1
2
3
Time (Minutes)
[A
U
]
NIX5 Cell Line
0 5 10 30 60 90 120
0.0
0.5
1.0
1.5
2.0
Time (Minutes)
[A
U
]
TRC Cell Line
Results'Normalized'to'TRC:
Figure 4.7E Serum Starvation Results – Probing for Upstream and Downstream 
Autophagy Proteins  
The TRC, NIX5 (BNIP3L KD), and ATG7 9 (ATG7 KD) cell lines were probed for the 
autophagy protein p62 following serum starvation by Western blotting. Graphed results are 
normalized to TRC values.  
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As shown in figures 4.7 A-E, the early, mid, and late-stage autophagy proteins are all 
upregulated at various time points in the ATG7 9, NIX5, and SQ11 cell lines compared to the 
transduced scramble control.  
 
4.8 Dose Response Data  
Cells were treated with a panel of drugs which were classified as DNA-targeting, 
mitochondrial-targeting, or an mTOR inhibitor. All dose response data was performed in 
triplicate. Results of the DNA-targeting panel (class I) are shown in figures 4.8 A-C. LD50 
values were calculated using the log (inhibitor) vs. response – variable slope (four parameters) 
non-linear fit on Graphpad Prism and are shown in table 4.5 a, b and c.  
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Figure 4.8A Dose Responses with DNA-Targeting Drugs: Cytarabine  
Cell lines ATG7, NIX, and SQ were run alongside TRC in dose-response studies with the 
DNA-targeting drug cytarabine. 
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Figure 4.8B Dose Responses with DNA-Targeting Drugs: Daunorubicin  
Cell lines ATG7, NIX, and SQ were run alongside TRC in dose-response studies with the 
DNA-targeting drug daunorubicin. 
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Figure 4.8C Dose Responses with DNA-Targeting Drugs: Doxorubicin  
Cell lines ATG7, NIX, and SQ were run alongside TRC in dose-response studies with the 
DNA-targeting drug doxorubicin. 
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Class I TRC TRC 95% 
Confidence 
Interval 
NIX1 NIX1 95% 
Confidence 
Interval 
NIX3 NIX3 95% 
Confidence 
Interval 
NIX5 NIX5 95% 
Confidence 
Interval 
Cytarabine 4.414 4.144 to 
4.702 
5.121 4.823 to 
5.437 
4.469 4.184 to 
4.773 
3.835 3.653 to 
4.025 
Daunorubicin 0.05825 0.05077 to 
0.06685 
0.05382 0.04764 to 
0.06079 
0.06338 0.05606 to 
0.07166 
0.06164 0.05354 to 
0.07096 
Doxorubicin 0.08029 0.07457 to 
0.08644 
0.06325 0.05983 to 
0.06687 
0.0807 0.07837 to 
0.08310 
0.08303 0.08076 to 
0.08537 
 
 
Class I 
TRC TRC 95% 
Confidence 
Interval 
SQ11 SQ11 95% 
Confidence Interval 
SQ12 SQ12 95% 
Confidence Interval 
Cytarabine 6.68 6.226 to 7.167 6.825 6.294 to 7.401 5.381 4.480 to 6.463 
Daunorubicin 0.05825 0.05077 to 0.06685 0.05412 0.04893 to 0.05986 0.06278 0.05612 to 0.07023 
Doxorubicin 0.08029 0.07457 to 0.08644 0.06168 0.05864 to 0.06488 0.07014 0.06826 to 0.07207 
 
 
Class I 
TRC TRC 95% 
Confidence 
Interval 
ATG7 6 ATG7 95% 
Confidence Interval 
ATG7 9 ATG7 9 95% 
Confidence Interval 
Cytarabine 5.378 4.702 to 6.150 5.205 4.793 to 5.652 4.604 4.098 to 5.173 
Daunorubicin 0.02368 0.01712 to 0.03277 0.01013 0.008168 to 0.01256 0.0133 0.01110 to 0.01593 
Doxorubicin 0.04757 0.02916 to 0.07761 0.04735 0.03548 to 0.06321 0.05335 0.03519 to 0.08089 
 
Results of the mitochondrial-targeting panel (class II) are shown in figures 4.9 A-E.  
LD50 values were calculated using the log (inhibitor) vs. response – variable slope (four 
parameters) non-linear fit on Graphpad Prism and are shown in table 4.6 a, b and c. 
Table 4.5a LD50 Values for Dose Responses with DNA-Targeting Drugs with the NIX 
Cell Lines  
    
Table 4.5b LD50 Values for Dose Responses with DNA-Targeting Drugs with the SQ 
Cell Lines  
    
Table 4.5c LD50 Values for Dose Responses with DNA-Targeting Drugs with the ATG7 
Cell Lines  
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Figure 4.9A Dose Responses with Mitochondrial-Targeting Drugs: Avocatin B  
ATG7, NIX, and SQ cell lines were run alongside TRC in dose-response studies with the 
mitochondrial-targeting drug avocatin B.  
 60 
 
 
ATG7
NIX
p62
FCCP
0 10 20 30 40 50
0
20
40
60
80
100
120
Drug Concentration (µM)
%
 V
ia
bl
e
TRC 
ATG7 6
ATG7 9
0 10 20 30 40 50
0
20
40
60
80
100
120
Drug Concentration (µM)
%
 V
ia
bl
e
TRC
NIX1
NIX3
NIX5
0 20 40 60 80 100
0
20
40
60
80
100
120
Drug Concentration (µM)
%
 V
ia
bl
e
TRC
SQSTM1 11
SQSTM1 12
B)
Figure 4.9B Dose Responses with Mitochondrial-Targeting Drugs: FCCP  
ATG7, NIX, and SQ cell lines were run alongside TRC in dose-response studies with the 
mitochondrial-targeting drug FCCP.  
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Figure 4.9C Dose Responses with Mitochondrial-Targeting Drugs: Oligomycin  
ATG7, NIX, and SQ cell lines were run alongside TRC in dose-response studies with the 
mitochondrial-targeting drug oligomycin. 
 
 62 
 
 
Rotenone
0 2 4 6 8
0
20
40
60
80
100
120
Drug Concentration (µM)
%
 V
ia
bl
e
TRC 
ATG7 6
ATG7 9
0 2 4 6 8
0
20
40
60
80
100
120
Drug Concentration (µM)
%
 V
ia
bl
e
TRC
NIX1
NIX3
NIX5
0 2 4 6 8
0
20
40
60
80
100
120
Drug Concentration (µM)
%
 V
ia
bl
e
TRC
SQ11
SQ12
ATG7
NIX
p62
D)
Figure 4.9D Dose Responses with Mitochondrial-Targeting Drugs: Rotenone  
ATG7, NIX, and SQ cell lines were run alongside TRC in dose-response studies with the 
mitochondrial-targeting drug rotenone. 
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Figure 4.9E Dose Responses with Mitochondrial-Targeting Drugs: Tigecycline 
ATG7, NIX, and SQ cell lines were run alongside TRC in dose-response studies with the 
mitochondrial-targeting drug tigecycine. 
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Class II TRC TRC 95% 
Confidence 
Interval 
NIX1 NIX1 95% 
Confidence 
Interval 
NIX3 NIX3 95% 
Confidence 
Interval 
NIX5 NIX5 95% 
Confidence 
Interval 
Avocatin B 24.62 22.62 to 26.80 17.51 16.89 to 18.16 9.453 8.98 to 8.95 8.78 5.79 to 13.31 
FCCP 12.77 10.33 to 15.80 1.28 0.3693 to 4.35 1.043 0.6954 to 1.57 0.004483 5.34e-005 to 
0.3757 
Oligomycin 12.57 11.61 to 13.61 11.31 10.23 to 12.50 10.24 9.38 to 11.19 8.475 7.00 to 10.27 
Rotenone 3.197 2.69 to 3.81 1.549 1.14 to 2.11 1.925 1.62 to 2.29 1.245 1.08 to 1.44 
Tigecycline 24.81 20.45 to 30.11 24.24 22.56 to 26.05 22.67 21.90 to 23.46 22.24 20.27 to 24.39 
 
 
Class II 
TRC TRC 95% 
Confidence 
Interval 
SQ11 SQ11 95% 
Confidence 
Interval 
SQ12 SQ12 95% 
Confidence 
Interval 
Avocatin B 23.90 21.11 to 27.05 15.19 12.06 to 19.12 11.13 9.13 to 13.56 
FCCP 21.13 18.73 to 23.83 3.955 2.07 to 7.57 5.727 2.18 to 15.05 
Oligomycin 12.57 11.61 to 13.61 10.91 10.00 to 11.92 11.05 10.11 to 12.08 
Rotenone 4.054 3.36 to 4.89 3.161 2.38 to 4.21 3.666 2.87 to 4.69 
Tigecycline 24.81 20.45 to 30.11 18.44 15.95 to 21.30 23.85 22.63 to 25.13 
 
 
Class II 
TRC TRC 95% 
Confidence 
Interval 
ATG7 6 ATG7 6 95% 
Confidence 
Interval 
ATG7 9 ATG7 9 95% 
Confidence 
Interval 
Avocatin B 24.62 22.62 to 26.80 18.35 16.35 to 20.60 26.14 23.70 to 28.83 
FCCP 10.56 9.364 to 11.92 6.349 5.698 to 7.074 0.3168 0.02734 to 3.671 
Oligomycin 12.57 11.61 to 13.61 11.11 10.02 to 12.31 12.53 11.67 to 13.45 
Rotenone 3.197 2.686 to 3.805 2.027 1.558 to 2.637 1.372 1.160 to 1.622 
Tigecycline 27.76 19.91 to 38.69 19.89 16.85 to 23.48 25.49 21.61 to 30.08 
 
Table 4.6a LD50 Values for Dose Responses with Mitochondrial-Targeting Drugs with 
the NIX Cell Lines  
 
Table 4.6b LD50 Values for Dose Responses with Mitochondrial-Targeting Drugs with 
the SQ Cell Lines  
 
Table 4.6c LD50 Values for Dose Responses with Mitochondrial-Targeting Drugs with 
the ATG7 Cell Lines  
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Results of the mTOR inhibitor, rapamycin (class III) are shown in figures 4.10 A.  LD50 values 
were calculated using the log (inhibitor) vs. response – variable slope (four parameters) non-
linear fit on Graphpad Prism and are shown in table 4.7 a, b and c. 
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Figure 4.10 A Dose Responses with the mTOR Inhibitor: Rapamycin  
ATG7, NIX, and SQ cell lines were run alongside TRC in dose-response studies with the 
mTOR inhibitor rapamycin.  
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Class III TRC TRC 95% 
Confidence 
Interval 
NIX1 NIX1 95% 
Confidence 
Interval 
NIX3 NIX3 95% 
Confidence 
Interval 
NIX5 NIX5 95% 
Confidence 
Interval 
Rapamycin 12.48 11.68 to 13.33 8.597 7.82 to 9.46 9.852 9.38 to 11.58 5.75 5.38 to 6.15 
 
 
Class III 
TRC TRC 95% 
Confidence 
Interval 
SQ11 SQ11 95% 
Confidence 
Interval 
SQ12 SQ12 95% 
Confidence 
Interval 
Rapamycin 11.13 10.38 to 11.94 8.412 7.59 to 9.32 8.144 7.59 to 8.74 
 
 
Class III 
TRC TRC 95% 
Confidence 
Interval 
ATG7 6 ATG7 6 95% 
Confidence 
Interval 
ATG7 9 ATG7 9 95% 
Confidence 
Interval 
Rapamycin 12.48 11.68 to 13.33 8.4 7.801 to 9.045 8.941 8.675 to 9.214 
 
As shown in figures 4.8-4.9 and tables 4.4- 4.5, all KD cell lines were increasingly 
sensitive to the majority of the mitochondrial-target panel and the mTOR inhibitor drug, however 
insensitive to the panel of DNA-targeting drugs.  
 
 
 
 
 
 
Table 4.7a LD50 Values for Dose Responses with an mTOR Inhibitor with the NIX Cell 
Lines  
 
Table 4.7b LD50 Values for Dose Responses with an mTOR Inhibitor with the SQ Cell 
Lines  
 
Table 4.7c LD50 Values for Dose Responses with an mTOR Inhibitor with the ATG7 
Cell Lines  
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Chapter 5: Discussion 
5.1 Analysis of Mitochondrial Function    
Using fluorescent dyes as probes, we sought to understand the mitochondrial 
transformations in our knockdown cell lines. ROS was measured to provide key data on 
mitochondrial health114. We utilized two fluorescent probes for ROS: DHE, which primarily 
reacts with superoxide, and H2DCFDA (fluorescent product: DCF), which is primarily used as a 
probe for hydrogen peroxide, but is known to additionally react with other ROS such as nitrate 
and hypochlorous acid 106,107,130,131,. Interestingly, our results indicate an increase in superoxide 
in all knockdown lines, however a decrease in the ROS associated with DCF fluorescence. 
Importantly, superoxide is the main mitochondria-derived ROS, produced from the electron 
transport chain (ETC) when the final electron acceptor, oxygen, is partially reduced46,132. 
Mitochondrial-derived ROS can escape the mitochondria and propagate oxidative chain reactions 
as well as damage proteins, lipids, and DNA46. Hydrogen peroxide can be produced by various 
oxidases as well as through the dismutation of superoxide, as shown in the reaction below133.  
 
Decreased activity of mitochondrial superoxide dismutase (Mn-SOD), the enzyme which carries 
out this reaction, has been shown to produce a ROS profile similar to our findings134,135. In 
concordance with our results, cells treated with the late-stage autophagy inhibitor bafilomycin 
A1 (BafA) showed decreases in DCF fluorescence and increases in DHE fluorescence with these 
results attributed to decreased SOD activity and expression136. The SOD alterations were 
postulated to be caused by increased degradation or stability changes brought on by protein 
O2! +"e! +""2H+""" H2O2
Mn!SOD
 69 
modifications136. DCF fluorescence could be further reduced by factors affecting the oxidation 
reaction with this dye. Oxidation of H2DCF by hydrogen peroxide to produce the fluorescent 
product DCF is dependent on enzymatic oxidation by a source of ferrous iron such as 
cytochrome c, which is released from mitochondria in a two-step process requiring membrane 
permeabilization137. Membrane permeabilization is facilitated by Bax, which is translocated to 
the membrane in a manner dependent on the loss of mitochondrial membrane potential138. 
Interestingly, we have shown that our knockdown lines have hyperpolarized mitochondrial 
membrane potentials, which may explain the decrease in fluorescence of the hydrogen peroxide 
indicator. Overall, the increase in superoxide in the absence of increases in other ROS suggests 
that this superoxide was mitochondria-derived and lends support to the hypothesis that 
deficiency of NIX, p62, and ATG7 causes accumulation of dysfunctional mitochondria that 
results in increases in mitochondrial ROS65,139.  
As the electron transport chain of mitochondria is associated with high levels of ROS 
production, we next sought to investigate whether increased ROS was related to alterations in the 
mitochondrial membrane potential (ΔΨM) – thus indicating altered mitochondrial function. The 
constant pumping of protons across their concentration gradient by the ETC creates a highly 
negative ΔΨM typically close to -180 mV140. The fluorescent dye Rhodamine 123, which is a 
lipophilic cationic dye, selectively accumulates in mitochondria in proportion to negative charge, 
allowing for analysis of ΔΨM 113. More negative (hyperpolarized) mitochondria accumulate 
more dye, resulting in increased fluorescence113. Our results indicate that knockdown of 
autophagy genes results in hyperpolarization of ΔΨM, a condition indicating dysfunction in the 
ETC141,142. Consistent with our results showing increased ETC-derived ROS, studies have shown 
that hyperpolarization of ΔΨM triggers uncoupling of the respiratory chain complexes, resulting 
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in increased ROS production143,144. Specifically, hyperpolarization has been shown to increase 
the NADH/NAD+ ratio causing decreases in the rate of electron flow, which subsequently 
prolongs the lifespan of reactive intermediates in the ETC that promote the formation of the 
superoxide anion102,143,132,145. Furthermore, ROS-induced damage can contribute to defects in the 
electron transport chain complexes, thereby mediating further changes to the mitochondrial 
membrane potential.146,147,148. Given that the strict coupling and maintenance of ΔΨM are 
necessary for efficient energy production through oxidative phosphorylation, and that 
mitochondrial hyperpolarization and ROS generation are common features in apoptosis induction 
in various cell types, accumulation of mitochondrial dysfunction as seen in autophagy-deficient 
cells would be expected to increase susceptibility to apoptosis149–151.  
 
5.2 Estimates of Mitochondrial Content  
 Given that knockdown of autophagy genes increased ROS and altered the mitochondrial 
membrane potential, we next sought to determine whether these knockdowns had any effect on 
the quantity of mitochondrial content in the cells.  Mitochondrial content was estimated using 
two methods: 1) cell staining using the fluorescent dye NAO and 2) quantification of mtDNA 
using qPCR. NAO is a dye which binds cardiolipin, a phospholipid which is almost exclusively 
found on the inner mitochondrial membrane where it is synthesized152. Due to its association 
with mitochondria-localized cardiolipin, NAO is commonly used as a measure of mitochondrial 
content153. Results of both the NAO and qPCR analysis showed flux over the course of the 
triplicate measures, with mitochondrial content values flipping above and below the TRC value 
over the course of the measurement cycle. Previous published data with ATG7−/− mice and 
various ATG7 knockout cell types showed increases in mitochondrial content as demonstrated 
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by increased fluorescence of MitoTracker agents62,64,154,155. As adaptor/receptor proteins of 
mitophagy, knockdown of BNIP3L (cell line: NIX) and SQSTM1 (cell line: SQ) is expected to 
increase mitochondrial content84,156. This discrepancy could be due to the use of knockdown 
instead of knockout in our study, as knockdown allows for mitochondrial clearance to still occur, 
albeit at a lower level. Dispersed measurements of mtDNA and NAO fluorescence may also 
have contributed to the increased flux seen in our data, as measurements with conditional ATG7 
knockouts would be run in quick succession due to impending lethality within 8-14 weeks64.   
The impact of ATG7 (cell line: ATG7), BNIP3L (cell line: NIX), and SQSTM1 (cell line: SQ) 
knockdowns on mitochondrial clearance could be further diminished by the presence of 
protective pathways in the cell. Indeed, as the small circular DNA of mitochondria is proximal to 
the ETC and has limited mechanisms for DNA-repair, ROS-induced damage to mtDNA may 
impair mitochondrial fission (replication) abilities leading to a decrease in mitochondrial content 
compared to a control undergoing regular mitochondrial fission 157. Furthermore, due to the 
compactness of the mitochondrial genome, it follows that mutations run a higher chance of 
affecting a gene product, which provides a new means for further production of dysfunctional 
elements of the ETC158,159,160.  
 
5.3 Cell Homeostasis Measurements  
Cell size, counts, and colony formation studies were run as a method of identifying 
substantial changes in cellular homeostasis. Mean cell size was not significantly altered in any of 
the knockdown cell lines. Increased cell size has been previously reported in ATG7 and ATG5 
knockout mice, whereby autophagy was established to be a negative regulator of cell size161–163.  
Recently published data suggests that regulation of cell size occurs at least in part through the 
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mevalonate pathway, which involves RAB11, a signaling molecule essential to basal autophagic 
flux161.  The lack of significant changes in cell size may reflect the use of knockdown instead of 
knockout in our study. Next, we measured cell proliferation via cell counts. Cell Proliferation is 
known to be controlled by cell size-dependent and independent mechanisms164. While 
proliferation in the TRC cell line increased in a stepwise manner, most knockdown cell lines 
demonstrated decreased proliferation or bi-directional changes in proliferation rate over the 
course of the measurements. Previous studies have shown that autophagy inhibition increases 
proliferation in various cancer cells via altered mTOR signaling and other factors (ex. Twist1 
stabilization for SQSTM1 knockdowns)76,165,166. The dysregulation seen in our cell lines could be 
caused by using knockdown instead of knockout. Our final measurement of cell homeostasis was 
colony formation. Colony forming abilities were diminished in the NIX cell line and unchanged 
in the ATG7 and SQ cell lines. These results were in accordance with most previously published 
knockdown and knockout data 167–172. It is worth noting that some conflicting reports have shown 
colony formation to be reduced in SQSTM1 knockdowns and increased in some ATG7 
knockdowns168,173,174. This disparity could be caused by differing levels of knockdown which 
would thus alter colony forming abilities to differing degrees (or not at all).  
 
5.4 Analysis of Upstream & Downstream Autophagy Response to Cellular Stress  
 As both cellular and mitochondrial dysfunction was demonstrated in the autophagy-
deficient cell lines, we next sought to understand the effects of these knockdowns on the 
dynamics of upstream and downstream autophagy proteins to give an indicator of the burden of 
these knockdowns on the process of autophagy. Autophagy is known to be upregulated in 
response to cellular stress signals such as nutrient deprivation175,176. Previous reports have 
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indicated that serum starvation elicits an acute autophagic response within minutes of nutrient 
deprivation which is mediated  by de-phosphorylation of the autophagy initiation factor 
ULK1177. In line with this, we ran our study along a similar 2-hour time course in buffered saline 
solution177. Beclin 1 and ATG7 represent early autophagy factors as they contribute to formation 
of the isolation membrane and vesicle elongation respectively, as shown in figure 1.4 of the 
introduction178. The conversion of LC3-I to LC3-II is a commonly used measure of autophagic 
flux as LC3-I conjugated to PE to create LC3-II during autophagy initiation, and LC3-II is then 
recruited to the autophagosome, where it acts as a cargo adaptor until it is degraded with the 
cargo179. NIX and p62 represent factors of late autophagy at the level of cargo recruitment as 
both can specifically act as adaptors/receptors of mitophagy47. Importantly, upregulation of all of 
these genes are part of the early response to nutrient deprivation180,181,182. The typical autophagic 
response demonstrated in the TRC cell line shows stepwise increases, and in some cases, 
subsequent decreases in autophagy proteins within the 2-hour assay. In response to serum 
starvation, AML cells deficient in ATG7, p62, and NIX demonstrated upregulation of all 
proteins of interest at various time points. Furthermore, all knockdowns show early upregulation 
of both mitochondrial cargo adaptors: NIX and p62, which suggests the presence of damaged 
mitochondria at the onset or soon after starvation initiation. 
Upregulation of autophagy factors during nutrient deprivation has been shown to be 
mediated by several mechanisms involving the production of ROS183. Indeed, superoxide and 
peroxide are produced by mitochondria during nutrient deprivation and positively regulate 
autophagy through activation of AMPK (which activates the ULK1 complex), inactivation of 
ATG4’s de-lipidating activity on LC3-II (leading to the accumulation of pro-autophagic LC3-II), 
and alterations to the thiol reduction state leading to an increase in ubiquitination of substrates183. 
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The increased production of ROS shown previously for all knockdown cell lines may contribute 
to the increases in autophagy flux compared to the transduced control.  Furthermore, the 
presence of damaged and dysfunctional mitochondria could contribute to the upregulation of 
autophagy, as selective mitochondrial clearance is activated as part of starvation-induced 
autophagy184,185. The more substantial changes in the ATG7 and NIX cell lines compared to the 
SQ cell line may reflect the essential vs dispensable nature of these proteins in the process of 
autophagy163,85. Indeed, redundancy has been shown to exist in this system whereby various 
adaptor proteins and receptors may function to link mitochondria to the autophagosome59. 
Deficiencies in adaptor proteins such as p62 may therefore not significantly affect the regulation 
of upstream autophagy proteins186.  Levels of knockdown could further affect the response seen 
in this assay, as increased levels of the knockdown protein may allow autophagy to proceed in a 
manner more similar to TRC187.   
Having shown increased stress-induced autophagy as demonstrated by upregulation of 
early and late stage autophagy proteins in response to starvation, we next sought to understand 
the dose-dependent response of our knockdown cells to an autophagy activating drug. When 
treated with Rapamycin, which exerts its effect by inhibiting mTOR (a main autophagy signaling 
center), all knockdown cell lines were increasingly sensitive to cell death compared to the TRC 
contro188,189. This sensitivity could be due to the cumulative effects of blocking autophagy at 
both the control center and autophagosome initiation/ cargo recruitment phases, resulting in the 
inability to perform stress-induced protective autophagy190.  
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5.5 Dose Response Data 
We next assessed the impact of autophagy gene knockdown on two classes of drugs 
organized as being class I: DNA-targeting, and class II: mitochondrial-targeting. The DNA-
targeting class was selected to represent standard AML therapeutics. Cytarabine is an 
antimetabolite drug which interferes with DNA synthesis whereas doxorubicin and daunorubicin 
are anthracyclines which impart their activity by intercalating with DNA and subsequently 
inhibit the progression of DNA topoisomerase II15,16. As expected, cytotoxicity of these DNA-
damaging agents was not affected by autophagy gene knockdown.  
Given that knockdown had no impact on cytotoxicity of DNA-targeting drugs, we next 
investigated a class of drugs which impart their activity by targeting mitochondria. The 
mechanisms of these agents affect mitochondrial function in various ways: blockage of the ETC, 
inhibition of ATP synthase, inhibition of fatty acid oxidation, etc. With exception of tigecycline, 
cytotoxicity of the mitochondrial-targeting drug class was increased by autophagy gene 
knockdown. Consistent with our previous indications of mitochondrial dysfunction imparted by 
increased ROS and altered mitochondrial membrane potential, our results suggest that 
autophagy-deficient cells are particularly sensitive to mitochondrial injury. The lack of 
sensitivity in KD lines treated with tigecycline may be explained by instability of this drug after 
reconstitution, as has been previously reported191.  
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Summary of Findings 
This study aimed to explore the relationship between autophagy and AML using genetic 
silencing of autophagy genes ATG7, SQSTM1, and BNIP3L. In particular, we were interested in 
the response of these cells to a panel of drugs with hopes of defining the value of using targeted 
chemotherapy in autophagy deficient cells. Our results have shown that knockdown of 
autophagy genes produces cells with various mitochondrial dysfunctions which we attributed to 
decreased clearance of damaged or dysfunctional mitochondria resulting from regular 
metabolism and further exacerbated by the accumulation ROS. These cell lines were increasingly 
sensitive to a panel of mitochondrial-targeting drugs with a broad range of mechanisms, which 
we similarly attributed to decreased clearance of damaged or dysfunctional mitochondria and 
increased mitochondrial ROS. The knockdown cell lines were also sensitive to an mTOR 
inhibitor, which may be linked to rapid depletion of autophagy proteins, preventing the 
protective autophagy effect. The results of this project are summarized in figure 5.0.  
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Overall, our results suggest that deficiencies in the gene products of ATG7, SQSTM1 and 
BNIP3L may be used as prognostic markers to determine sensitivity to mitochondrial target 
drugs. Tailored therapies yield promise in the new age of chemotherapy as they provide a means 
to exploit specific dysfunctions known to be present in a cell population. 
 
 
 
Knockdown	  of	  Autophagy	  Genes
Cell	  Growth	  Indicators
Proliferation[Dysregulated]
Colony	  Formation[Unaltered]*
Cell	  Size[Unaltered]
Mitochondrial	  Indicators
Mitochondrial	  ROS[Elevated]
Other	  ROS[Decreased]
ΔΨM	  [Hyperpolarized]
Mitochondrial	  Quantity[Unaltered]
Autophagic	  Response
Starvation	  Response	  [Altered]
Activation	  Response	  [Altered]
Drug	  Response
DNA-­‐‑Targeting	  Drugs[Insensitive]
Mitochondrial-­‐‑Targeting	  Drugs[Sensitive]
Figure 5.0 Study Summary 
 Knockdown of autophagy genes led to dysregulation of cell proliferation, increased 
mitochondrial ROS, decreased levels of other ROS, hyperpolarized ΔΨM, altered autophagy 
activation responses when stimulated by starvation and chemical means, and finally increased 
sensitivity to mitochondrial-targeting drugs.  
*Exception: NIX1 
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Limitations 
This research explored the topic of single autophagy gene defects on mitochondrial 
sensitivity, however in a real-life scenario, it is possible (and most likely) that a variety of 
genetic dysfunctions exist in the patient192. AML is known to be a highly heterogeneous disease 
between patients, within a patient, and over the course of disease progression192,193,194. Further 
studies using the commonly grouped genetic defects seen in patients would provide more 
translatable data which could be applied to specific patient populations. As loss of genetic 
material in particular chromosomal regions is common in AML, inclusion of autophagy genes 
which reside in these regions would provide a good starting point for these studies66.   
 
Since an all-encompassing study of autophagy proteins was not feasible, we focused our 
study instead on three autophagy proteins which would serve to exemplify autophagic deficiency 
at two key stages: autophagosome formation (ATG7), and cargo recruitment (p62 and NIX). 
Further studies with other autophagy proteins and mitochondrial adaptors/receptors should be 
undertaken to create database of defects which confer sensitivity to mitochondria and m-TOR-
targeting drugs.   
The measures of mitochondrial characteristics used in this project provided a means to 
quantify ROS, mitochondrial content, and the ΔΨM. Various other dyes and assays could be 
used to further detect dysfunction in the mitochondria. MitoSOX Red provides a means to detect 
superoxide within the mitochondria195. MitoTracker Green provides another means to measure 
mitochondrial mass in a manner which is independent of ΔΨM196. Other mitochondrial genes 
could be probed for to validate the ND1 measurements197.  
 79 
We selected three classes of drugs for the purpose of this study: DNA-targeting, 
mitochondrial-targeting, and an mTOR inhibitor. The DNA-targeting class was selected to 
represent standard AML therapeutics, the mitochondrial-targeting class was selected as we were 
expecting an accumulation of mitochondrial dysfunction in our cells, and the mTOR inhibitor 
was selected as inhibition of mTOR activates autophagy. At present, mitochondrial-targeting 
drugs are not commonly used to treat AML198. Further study could uncover other drug classes for 
which the KD lines are sensitive, such as drugs which effect ROS levels or regulators of cell 
homeostasis.  
The ultimate utility of this study relies on detection of autophagic dysfunction in AML 
patients. Karyotyping provides information on chromosomal loss of autophagy genes and 
provides a starting point for detecting dysfunction66. Proteomics, the study of an organism’s 
entire set of proteins, yields the most hope for providing personalized cancer care, as it can detect 
differences brought on by transcriptional regulation199. Although the use of proteomics in cancer 
care currently resides in the research domain, this emerging field, when employed, could provide 
the foundation for application of this research199. 
 
Conclusions  
In this study, we sought to better understand the mitochondria-specific changes in AML2 
cells with deficits of autophagy proteins ATG7, NIX, or p62 by measuring a variety of 
mitochondrial health and function markers. Our results indicate that knockdown of our proteins 
of interest cause an abnormal mitochondrial phenotype that results in increased sensitivity to 
mitochondrial target drugs. Our research is particularly significant as some AML patient 
populations have been shown to be deficient in autophagy proteins165. Furthermore, an altered 
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mitochondrial phenotype is a feature of AML77,78,79. Given the low survival rate of adult AML, 
our results suggest that pharmacological approaches which target mitochondria should be 
explored, as AML patients with autophagic deficiencies would be particularly sensitive to these 
drugs. Furthermore, once mitochondrial drugs for AML are approved, autophagy deficiencies 
may provide a useful prognostic indictaor for patients receiveing these therapies.  
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